logo
If You Bought 100 Shares of IonQ at Its IPO, Here's How Much Money You'd Have Now

If You Bought 100 Shares of IonQ at Its IPO, Here's How Much Money You'd Have Now

Globe and Mail2 days ago
Key Points
IonQ began trading on public markets in 2021 after merging with a special purpose acquisition company.
Shares of IonQ have soared over the past four years.
The stock has plenty of potential to continue rising as the quantum computing industry matures.
10 stocks we like better than IonQ ›
With the potential to revolutionize computing as we know it, quantum computing has soared in popularity among investors seeking tech stocks with ample growth opportunity. Of the limited number of quantum computing stocks, IonQ (NYSE: IONQ), a leader in the field, is one of the most recognizable names.
But a stock growing in popularity doesn't always ensure that shares will also rise. Let's see how IonQ investors who bought shares four years ago after the company's debut on public markets have fared.
The first quantum computing company on the scene
Proclaiming itself the "first publicly traded, pure-play quantum computing company," IonQ began trading on Oct. 1, 2021 at $10.60 after the company completed a merger with a special purpose acquisition company (SPAC). Over the following years, the company has announced several notable achievements.
From opening the first quantum computing manufacturing facility in the United States, to applying quantum computing to artificial intelligence (AI) and machine learning that advances hybrid quantum-classical computing to improve both large language models and generative AI, IonQ has made tremendous strides that have excited investors' interest.
As a result of the company's progress, shares of IonQ have soared. People who invested $1,060 to buy 100 shares at the stock's open on the first day of trading at it's opening price had seen their positions grow to $4,122 as of the end of trading on Aug. 6, 2025.
Is it a quantum leap to think that IonQ stock can rise further?
As a leader in the burgeoning quantum computing field, IonQ stock is one of the most common considerations for investors seeking exposure to the cutting-edge technology. While quantum computing might seem the stuff of science fiction, the company is demonstrating that there's nothing fictitious about the technology. As it pursues integrating its technology with hyperscalers like Microsoft Azure and Amazon Web Services, the company has robust growth potential over the coming years, and there's the definite potential for IonQ stock to continuing surging higher.
Should you invest $1,000 in IonQ right now?
Before you buy stock in IonQ, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and IonQ wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $619,036!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,092,648!*
Now, it's worth noting Stock Advisor's total average return is 1,026% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of August 4, 2025
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why Nektar Therapeutics Stock Popped 6% on Friday
Why Nektar Therapeutics Stock Popped 6% on Friday

Globe and Mail

time4 minutes ago

  • Globe and Mail

Why Nektar Therapeutics Stock Popped 6% on Friday

Key Points Investors were reacting to the biotech's second-quarter earnings report. Revenue was higher than analysts expected, although the net loss was deeper than the consensus. 10 stocks we like better than Nektar Therapeutics › Biotech Nektar Therapeutics (NASDAQ: NKTR) unveiled its latest quarterly earnings after the stock market's close on Thursday, and the investor reaction was strong the following day. Happily for Nektar, it was largely positive, and the share price increased by 6% today. This was well higher than the 0.8% gain posted by the S&P 500 index. Sweet results In its second quarter, Nektar booked total revenue of just under $11.2 million, which was less than half of the nearly $23.5 million in the same period of 2024. All of this derived from noncash royalty revenue connected to the sales of future royalties. This isn't unusual for a biotech without a commercialized product that depends on royalties and other payouts from partners. Nektar added that its cash and investments in marketable securities stood at just under $176 million at the end of the quarter (June 30). That, plus the roughly $107.5 million it should reap from a recent secondary share issue, should fund its operations into the first quarter of 2027. Meanwhile, the company's net loss for the second quarter was slightly over $39 million, or $2.78 per share. On average, analysts were projecting Nektar would book $9.7 million in revenue and a net loss of only $0.20 per share. I should note here that it can be challenging for even the most experienced professionals to estimate the results of biotechs that don't draw meaningful revenue from commercialized products. On a fast track All that said, there are several potential tailwinds for Nektar just now, and the company wasn't shy about itemizing them in its earnings release. Among the more promising is the U.S. Food and Drug Administration granting its Fast Track designation for rezpegaldesleukin, Nektar's investigational drug targeting severe-to-very-severe alopecia areata (a skin disorder). Should you invest $1,000 in Nektar Therapeutics right now? Before you buy stock in Nektar Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nektar Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,563!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,108,033!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store